AZD2962 clinical trials

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

This study is testing a new drug, AZD2962, for people in the UK with certain blood cancers, like myelodysplastic syndromes (MDS). It aims to see how safe the drug is, how the body handles it, and if it might help to treat these conditions, either alone or with other medicines.